key: cord-0746833-jdq859xc
authors: Czajka, Timothy F.; Vance, David J.; Mantis, Nicholas J.
title: Slaying SARS-CoV-2 One (Single-Domain) Antibody at a Time
date: 2020-12-16
journal: Trends Microbiol
DOI: 10.1016/j.tim.2020.12.006
sha: 23b7608f06115c5302c55dba83487215a25f194a
doc_id: 746833
cord_uid: jdq859xc

Camelid-derived and synthetic single-domain antibodies (sdAbs) are emerging as potent weapons against the novel coronavirus, SARS-CoV-2. SdAbs are small, compact, thermostable immunoglobulin elements capable of binding targets with sub-nanomolar affinities. By leveraging the power of phage- and yeast surface-display technologies, rare sdAbs can be isolated from highly diverse and complex antibody libraries. Once in hand, sdAbs can be engineered to improve binding affinity, avidity, target specificities, and bio-distribution. In this Opinion piece, we highlight a series of sophisticated studies describing the identification of ultrapotent sdAbs directed against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein. We discuss the possible applications of these antibodies in the global fight against COVID-19.

The highly contagious novel coronavirus, SARS-CoV-2, continues to infect tens of millions worldwide, with the estimated number of deaths from COVID-19 fast approaching two million. SARS-CoV-2 is a spherical particle containing a 30 kb positivesense RNA genome associated with a nucleocapsid core surrounded by an envelope . The surface of SARS-CoV-2 is studded with ~40 copies of a trimeric club-shaped glycoprotein called Spike (Turonova et al., 2020; Wrapp et al., 2020b) .

Spike's so-called receptor binding domain (RBD) promotes virus attachment to host cells via angiotensin converting enzyme 2 (ACE2) (Benton et al., 2020; Hoffmann et al., 2020) . From what is known about other coronaviruses, the SARS-CoV-2 Spike undergoes a conformation change following ACE2 binding that results in membrane fusion and delivery of the virus and its genomic contents into the cytoplasm of host cells, where replication ensues (Walls et al., 2017) . SARS-CoV-2 infection of the airways triggers an inflammatory cytokine storm that can progress to life-threatening acute respiratory distress syndrome (ARDS) (Fajgenbaum and June, 2020; Vabret et al., 2020) .

The devastating impact of the SARS-CoV-2 pandemic has mobilized efforts around the globe to develop drugs, vaccines and other intervention strategies to arrest the novel coronavirus in its tracks and stop the spread of COVID-19. Of particular interest is a series of recent reports describing camelid-derived and synthetic single-domain antibodies (sdAbs) with potent (nanomolar) and even ultrapotent (picomolar) SARS-chain (H) and light chain (L) pair homodimerize to form a "Y" shaped molecule (150 kDa) (Figure 1) . The variable domains of the H (V H ) and L (V L ) chains of each arm of the "Y" are in close spatial proximity to each other and form a single interface involved in target (antigen) recognition. The V H and V L elements each contain three hypervariable complementarity determining regions (CDRs) that, over the course of an immune response, may undergo multiple rounds of affinity maturation to achieve a "best fit" with a pathogen target (Mesin et al., 2016) . While it is not uncommon that V H elements dominate an antibody-antigen interaction, rarely does a V H or V L element on its own have sufficient affinity to engage with an antigen.

Heavy chain-only antibodies (HCAbs) are different. First discovered in Arabian camels (Camelus dromedarius), HCAbs are now known to be present across the Camelidae family, including llamas and alpacas (Hamers-Casterman et al., 1993) .

HCAbs consist of two heavy chains (homodimers) without light chain partners ( Figure   1 ). Antigen recognition is confined to the terminal V H domain or V H H. Similar to the V H domains of conventional immunoglobulins, HCAb V H H domains or sdAbs consist of nine -strands arranged in two-sheets with CDR 1-3 elements located on one face. For reasons having to do with the absence of a light chain, V H Hs have a propensity for concave surfaces including active sites and receptor binding pockets (De Genst et al., 2006; Rudolph et al., 2020) . Indeed, V H Hs are notorious for their ability to contact catalytic resides and mimic substrates. For a thorough discussion of the evolution, immunology, structural biology of V H Hs, we refer the reader to comprehensive reviews on the subject (Muyldermans, 2020b) .

What makes sdAbs so appealing is that they retain affinity and specificity for target antigens when expressed as recombinant fusion proteins on the surface of bacteriophage M13 ("phage display") or yeast ("yeast display") (Muyldermans, 2020a) .

In the case of phage display, antibodies are isolated by subjecting the phage-display libraries to repeated rounds of affinity selection on antigen-coated tubes or magnetic beads (Figure 2) . While specific methodologies are beyond the scope of this article, reiterative enrichment strategies enable the isolation of exceedingly rare sdAbs from large and diverse antibody libraries. Moreover, because the V H H-coding DNA is J o u r n a l P r e -p r o o f Journal Pre-proof packaged within the isolated phage particle or yeast cells, antibodies are readily cloned and expressed in E. coli.

Single-domain antibody libraries come in three flavors: immune, naïve and synthetic ( Figure 2) . Immune libraries are generated from camelids that have been immunized (often repeatedly) with antigens of interest (Muyldermans, 2020b) . The primary advantage of such libraries is that they are enriched in antigen-specific sdAbs that arose as a result of natural, immune-mediated affinity-maturation, thereby greatly increasing the yield and diversity of high-affinity antibodies (low or sub-nanomolar) against desired targets. Indeed, two rounds of selection with such libraries can yield families of antibodies with extraordinary high binding affinities. However, immune libraries are not accessible to everyone, as they require access to camelids, large amounts of antigen for immunizations, and the technical expertise necessary to assemble and validate a diverse and complex phage-or yeast-display library.

Naïve and synthetic libraries, on the other hand, are commercially available and theoretically ready at a moment's notice. Naïve libraries are derived from pre-existing B cell repertoires of one or more non-immunized animals, while synthetic libraries are constructed in vitro using a combination of bioinformatics and structural biology information available in GenBank and the PDB (McMahon et al., 2018) . In either case, once constructed, the power of phage-and yeast-display technologies enables the isolation of rare sdAbs against targets of interest. However, synthetic and naïve libraries generally yield sdAbs of lower affinities than immune libraries, thereby necessitating in vitro affinity maturation and further rounds of screening to obtain sdAbs with low or subnanomolar activities (Schoof et al., 2020; Wellner et al., 2020; Xiang et al., 2020) . the most potent RBD-specific sdAbs and speculate as to their potential to contribute to the fight against COVID-19.

The first sdAbs with SARS-CoV-2 neutralizing activity were reported within months of the appearance of the novel coronavirus onto the world's stage (Wrapp et al., 2020a) .

By chance, Wrapp and colleagues had generated a V H H-phage display library from a llama immunized with the Spike proteins of two related human beta coronaviruses, MERS and SARS-CoV-1 (de Wit et al., 2016) . The Spike proteins of SARS-CoV-1 and SARS-CoV-2 are ~75 % similar to each other (Wan et al., 2020) . One sdAb, called VHH-72, was identified as targeting the RBD of SARS-CoV-1 Spike protein, but reacted with an epitope shared with SARS-CoV-2 RBD. The structure of VHH-72 bound to SARS-CoV-1 RBD revealed its binding site as being outside the ACE2 receptor binding motif (Figure 2) . While VHH-72 by itself was not particularly potent, its SARS-CoV-2 neutralizing activity was greatly enhanced when it was expressed as a bivalent human Fc IgG fusion protein (Table 1; Figure 3 ).

In a more concerted effort to target the SARS-CoV-2 RBD specifically, Hanke and colleagues immunized an alpaca with a cocktail of the S1 subunit of the Spike protein and isolated RBD ( Table 1 ) (Hanke et al., 2020) . As depicted in Figure 2 , the investigators cloned V H H-encoding genes from the alpaca into an M13 vector and subjected the resulting V H H-phage display library to two rounds of affinity enrichment with immobilized RBD as "bait". Next-generation sequencing (NGS) revealed that the panning strategy resulted in a ~10,000-fold enrichment for RBD-specific antibodies. A single RBD-specific V H H, named Ty1 was identified. Ty1 blocked RBD-ACE2 interactions and neutralized SARS-CoV-2 pseudoviruses ( Table 1) . The structure of Ty1 in complex with the SARS-CoV-2 trimeric Spike revealed Ty1's epitope as being within the region of RBD known as the receptor binding motif (RBM), which interacts directly with ACE2 (Figure 2) .

In a study in Science, Xiang and colleagues upped the ante by describing the isolation of ~350 unique sdAbs against SARS-CoV-2 RBD from a V H H-phage display library derived from a single RBD-immunized llama (Xiang et al., 2020) . The remarkable yield of unique sdAbs was achieved using an integrative proteomics pipeline. A series of down selection strategies eventually yielded 18 unique sdAbs with low nanomolar and J o u r n a l P r e -p r o o f Journal Pre-proof even sub-nanomolar affinities for RBD and potent neutralizing activities against the SARS-COV-2 Munich strain ( Table 1) . Through a series of competitive binding assays and cross-linking studies, the investigators identified five distinct epitopes on RBD with the ACE2 interface region being the most immunodominant. The investigators solved the crystal structure of a particularly potent sdAb, Nb20, bound to RDB (Table 1) .

Synthetic and naïve phage and yeast-display libraries have also yielded high-affinity sdAbs against SARS-CoV-2. In a report in Nature Structural and Molecular Biology, Huo and colleagues screened for RBD-specific sdAbs from a V H H-phage display library derived from a naïve llama ( Table 1) . The screen yielded a single low affinity RBDspecific V H H, H11. In an effort to improve the binding characteristics of H11, the CDR3 element was subjected to random mutagenesis, cloned into a V H H-phage display vector and re-panned on RBD. Ultimately, the screens gave rise to two derivatives, H11-D4 and H11-H4, that bound RBD with 20-50-fold improved affinity compared to H11. Both H11-D4 and H11-H4 blocked RBD interactions with ACE2 and neutralized SARS-CoV-2 in vitro ( Table 1 ). The structures of the two V H Hs in complex with RBD were solved and, remarkably, recognize virtually the same epitope on RBD as Ty1 (Figure 2 ).

Schoof and colleagues took a different tack and used a commercially available synthetic V H H yeast-display library to fish for sdAbs capable of recognizing RBD with trimeric full-length Spike as bait (Schoof et al., 2020) . In their article in Science, they describe a screen that involved a combination of magnetic bead-based enrichment and fluorescence-activated cell sorting, which ultimately uncovered 21 unique sdAbs. The sdAbs fell into two classes: Class I bound RBD and competed with ACE2; class II recognized RBD, but outside the ACE2 interface. Class I sdAbs, notably Nb6, proved to be the most effective at neutralizing SARS-COV-2 ( Table 1) . The cryo-EM structure of Nb6 in complex with trimeric Spike revealed that the antibody recognizes RBD in a "closed" or down conformation (Figure 2) . Moreover, Nb6 interacts simultaneously with two adjacent RBDs, effectively disabling two of the three RBD elements from being able to interact with ACE2. Using this information, the investigators engineered bivalent and and Nb6 were expressed as IgG1 Fc fusion proteins (Hanke et al., 2020; Huo et al., 2020; Schoof et al., 2020; Wrapp et al., 2020a; Xiang et al., 2020) .

We now confront the question of how the armamentarium of newly discovered ultrapotent RBD-specific sdAbs can contribute to the battle against SARS-CoV-2. The immediate next step is to determine whether the newly identified sdAbs are able to neutralize SARS-CoV-2 in an animal model of COVID-19 (Hewitt et al., 2020) . In this respect, two recent reports in PNAS and Cell provide a roadmap going forward (Li et al., 2020a; Li et al., 2020b) . In those reports, Li and colleagues isolated, by phage-display technologies, human sdAbs against RBD and tested them as recombinant IgGs in three different animal models: wild type mice challenged intranasally with a mouse-adapted SARS-CoV-2 strain, human ACE2-transgenic mice challenged intranasally with SARS-CoV-2, and Syrian golden hamsters challenged intranasally with SARS-CoV-2.

Antibodies were administered by injection before or after virus exposure and protection was assessed by viral load and lung histopathology at different time points after challenge. The investigators also performed dose-response studies and some limited pharmacokinetic analyses, thereby providing important benchmarks by which other sdAbs can now be evaluated.

If one or more of the camelid-derived ultrapotent RBD-specific sdAbs showcased above prove effective in animal models of COVID-19, then clinical studies may be warranted. There is also precedent in this realm. In 2019, the first single sdAb-based biologic, Caplacizumab, was approved by the FDA to treat a rare blood clotting disorder (Morrison, 2019) . Caplacizumab is a llama-derived sdAb that has been genetically engineered to resemble human-derived V H elements ("humanized") (Ulrichts et al., 2011) . Moreover, the humanized sdAb was dimerized (i.e., two identical sdAbs are joined via an alanine linker) to create a bivalent molecule, which is expressed in E. coli (Callewaert et al., 2012) . It is now approved for use in the United States and abroad (Morrison, 2019) .

If a SARS-CoV-2 sdAb successfully makes it through pre-clinical and clinical testing regimens, the next consideration is whether it can compete with the MAb-based therapies from Eli Lilly (Chen et al., 2020) and Regeneron (Baum et al., 2020) are human IgGs that target the SARS-CoV-2 Spike RBD and block ACE2 interactions (Baum et al., 2020; Chen et al., 2020; Hansen et al., 2020) Attacking SARS-CoV-2 on the front lines (of the airways and gut). However, the future of sdAbs may not be so much going head-to-head with existing human MAb therapies for COVID-19, but, rather, venturing into territories where conventional MAbs cannot tread. Perhaps the most exciting prospect is direct delivery of sdAbs into the lungs as a strategy to intercept SARS-CoV-2 before it accesses ACE2 and takes up residence within airway epithelial cells (Hanke et al., 2020; Huo et al., 2020; Schoof et al., 2020; Wrapp et al., 2020a; Xiang et al., 2020) . As noted by others, the small size and intrinsic thermostability of sdAbs make them particularly attractive as candidates for aerosol or particle delivery (Schoof et al., 2020; Xiang et al., 2020) . Indeed, direct J o u r n a l P r e -p r o o f Journal Pre-proof delivery or in situ expression of sdAbs within the context of respiratory infections is an area of active pursuit (Respaud et al., 2016) . For example, a recently completed Phase 2b clinical trial evaluated a trivalent sdAb called ALX-0171, as treatment for respiratory syncytial virus (RSV) infection (Cunningham et al., 2020) . Children admitted to hospital for acute severe RSV received two doses of ALX-0171 by nebulizer. Patients that received ALX-0171 cleared RSV, as detected in nasal swabs, faster than the placebo group, demonstrating the ability of passively administered antibody to clear virus from the upper airways. Although the clinical course of RSV infection was not altered by ALX-0171 intervention, the study nonetheless represents a milestone in the application of sdAbs to severe respiratory virus infections, including COVID-19.

Other delivery platforms and strategies should be considered when confronting SARS-CoV-2 (Figure 3) . Ian Wilson's group at The Scripps Research Institute, for example, used structure-based design to engineer a multimeric, multiepitope targeted, sdAb fusion protein (MD3606) with against influenza virus (Laursen et al., 2018) .

MD3606 is truly an engineering feat in that it consists of three different sdAbs linked in tandem and dimerized by fusion with the Fc region of human IgG1. Mice that received MD3606 by injection or recombinant adeno-associated virus (AAV)-mediated gene delivery were protected from lethal dose influenza A and B virus challenge.

SdAb applications do not need to be limited to the lung. SARS-CoV-2 is also found at high levels in the gastrointestinal tract and shedding of virus in the stools can occur in asymptomatic individuals (Gaebler et al., 2020; Trypsteen et al., 2020) . IgA is the primary antibody type found in mucosal secretions, including saliva, the upper airways and especially the gastrointestinal tract (Figure 3) . In the context of the gut, it was recently shown that passively administered recombinant sdAb-IgA fusion proteins have biological activity. Specifically, an sdAb-IgA construct given to piglets in their feed was sufficient to protect them against an experimental enterotoxigenic E. coli infection (De Greve et al., 2020; Virdi et al., 2019) . The prospect of IgA-based sdAbs is particularly exciting considering that several reports indicated that human IgA is able to neutralize SARS-CoV-2 better than IgG (Ejemel et al., 2020; Wang et al., 2020) Finally, with the advent of nucleic acid-based vaccines for SARS-CoV-2 now a reality, it is likely that mRNA-based antibody prophylactic or therapeutic strategies will J o u r n a l P r e -p r o o f Journal Pre-proof soon follow with sdAbs leading the way. In fact, it has already been shown that a single injection of mRNA-lipid nanoparticles encoding engineered botulinum toxin sdAbs into mice resulted in serum antibody responses capable of affording immunity to a lethal toxin challenge (Thran et al., 2017) . We have reported that alpaca-derived sdAbs targeting the active site of ricin toxin were able to neutralize the toxin when expressed as intrabodies in the cytoplasm of Vero cells (Rudolph et al., 2020) . In fact, it is not farfetched to think that sdAbs might be identified that could function intracellularly to interfere with SARS-CoV-2 machinery involved in entry, replication or host cell egress considering that a group from Wuhan University reported on this strategy for influenza virus more than decade ago (Mukhtar et al., 2009) . For a more elaborate discussion on targeting virus machinery within infected cells, see De Vlieger et al. (De Vlieger et al., 2018) .

is imperative that all avenues be pursued to arrest the spread of the novel coronavirus.

If the results of the past several months are any indication, the prospect of sdAbs contributing to the fight against SARS-CoV-2 is high. Particularly intriguing is the prospect of delivering sdAbs directly into the lung as a means of slaying SARS-CoV-2 before it gains a foothold in host cells. In terms of basic research, the sdAbs described to date have identified critical contact points on RBD involved in ACE2 interaction and demonstrated that these epitopes constitute sites of vulnerability on the surface of SARS-CoV-2. Finally, although not discussed in detail, the ultrahigh affinity SARS-CoV-2-specific sdAbs may have utility as diagnostic tools (De Meyer et al., 2014) . SdAbs can serve as cost-effective standards for ELISAs or virus neutralizing assays. The thermostability of sdAbs coupled makes them particularly attractive for point of care diagnostic applications. One could envision the use of high-affinity, high-specificity sdAbs in antigen-based detection platforms like SARS-CoV-2 lateral flow devices with saliva. 

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

High Potency of a Bivalent Human V(H) Domain in SARS-CoV-2 Animal Models

The Architecture of Inactivated SARS-CoV-2 with Postfusion

Nanobody approval gives domain antibodies a boost

Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription

Applications of Nanobodies

A guide to: generation and design of nanobodies

CoV-AbDab: the Coronavirus Antibody Database. Bioinformatics

Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin

Intracellular Neutralization of Ricin Toxin by Single-domain Antibodies Targeting the Active Site

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

On the whereabouts of SARS-CoV-2 in the human body: A systematic review

In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Immunology of COVID-19: Current State of the Science

Yeast-secreted, dried and food-admixed monomeric IgA prevents gastrointestinal infection in a piglet model

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Rapid generation of potent antibodies by autonomous hypermutation in yeast

Structural J o u r n a l P r e -p r o o f Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science

Journal Pre-proof